Novartis Ag

Dana-farber-cancer Institute Inc.

Other

The General Hospital Corporation

Les Laboratories Servier

Les Laboratoires Servier

Dale Porter

Kornelia Polyak

Dennis Sgroi

Ian Krop

Pascal Furet

Robin Alec Fairhurst

Robert Mah

Bo Han

Catherine Leblanc

Can Wang

Lv Liao

Jing Xiong

Nicole Buschmann

Caroline Emery

Xianglin Zhao

Diana Graus Porta

Olivier Geneste

Matthew J LaMarche

Jorge Garcia Fortanet

Guillaume Laurent Lessene

Maïa Chanrion

Markus Wartmann

Thomas Knöpfel

Thomas Knoepfel

John Scott Cameron

Sebastien Ripoche

Pierre Nimsgern

Youzhen Wang

Ensar Halilovic

Geoffrey Lindeman

Jane Visvader

Padmaja Yerramilli-Rao

Ana Leticia Maragno

Pankaj Seth

François Vaillant

Andreas Weiss

Elisabetta Marangoni

Francois Vaillant

Giovanna Pomilio

Donia Moujalled

Andrew Wei

Li Wang

Douglas Robinson

Carolina Haefliger

Masato Murakami

Michael Palmer

Nafeeza Hafeez

James Whittle

Delphine Merino

Lujian Tan

Kavitha Venkatesan

Maia Chanrion

Sneha Sanghavi

Prakash Mistry

Heiko Maacke

Thomas KNÖPFEL

A combination comprising a MCL-1 inhibitor and a taxane compound, and compositions and uses thereof.

Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof

The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof 

Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Pharmaceutical combinations

A pharmaceutical combination comprising (a) a protein kinase C (PKC) inhibitor compound, or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

A method of selecting a subject having cancer for treatment with an IAP inhibitor.

Biomarkers for IAP inhibitor therapy

This invention encompasses antibodies specific for IBC-1 (Invasive Breast Cancer-1), methods for diagnosis and prognosis of metastatic breast cancer and degenerative neural conditions, methods of identifying and manufacturing therapeutic compounds, and methods of treating patients with invasive and metastatic breast cancer or degenerative neural conditions.

IBC-1 (Invasive Breast Cancer-1), a putative oncogene amplified in breast cancer

The invention encompasses isolated DNAs encoding HIN-1 polypeptides, vectors containing such DNAs, cells containing the vectors, and isolated HIN-1 polypeptides. The invention also features methods of making and using HIN-1 polypeptides.

HIN-1, a tumor suppressor gene

IBC-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer

Growing community of inventors

Cambridge, MA, United States of America

Dale Porter